Lymphatic Drainage Dysfunction is Related to Clinically Significant Portal Hypertension
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Jeong J, Tanaka M, Iwakiri Y
. Hepatic lymphatic vascular system in health and disease. J Hepatol. 2022; 77(1):206-218.
PMC: 9870070.
DOI: 10.1016/j.jhep.2022.01.025.
View
2.
Park S, Kim T, Ham S, Um S, Goh H, Lee S
. Clinical implications of thoracic duct dilatation in patients with chronic liver disease. Medicine (Baltimore). 2020; 99(22):e19889.
DOI: 10.1097/MD.0000000000019889.
View
3.
Hirooka M, Koizumi Y, Yano R, Nakamura Y, Sunago K, Yukimoto A
. Cisterna chyli as an optimal marker of tolvaptan response in severe cirrhotic ascites. Sci Rep. 2022; 12(1):8124.
PMC: 9114325.
DOI: 10.1038/s41598-022-11889-z.
View
4.
Tanaka T, Koga H, Suzuki H, Iwamoto H, Sakaue T, Masuda A
. Anti-PD-L1 antibodies promote cellular proliferation by activating the PD-L1-AXL signal relay in liver cancer cells. Hepatol Int. 2023; 18(3):984-997.
DOI: 10.1007/s12072-023-10572-3.
View
5.
De Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C
. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022; 76(4):959-974.
PMC: 11090185.
DOI: 10.1016/j.jhep.2021.12.022.
View